This Small Elite Group Made Millions From Coronavirus
By GreatGameIndia - March 4, 2020
While the outbreak has claimed more than 3000 lives officially, this small elite group made millions from Coronavirus, courtesy of their association with the biotechs working on Coronavirus vaccine development programs.
The $35 billion vaccine market is dominated by GlaxoSmithKline, Sanofi Adventis, Merck and Pfizer. These 4 players represent 85% of the vaccine market. These are the primary players but are by no means alone because there is a global rush out there.
Three biotech stocks are surging on the possibility of coronavirus drugs and minting millions of dollars for their biggest shareholders. Gilead, Moderna, and Novavax have all outperformed the falling stock market in recent days as the three drug developers rush to introduce preventative vaccines and treatments.
Here are the seven venture capitalists, scientists, and executives who made millions from the surging biotechs, ranked in ascending order of gains. Profit data is calculated from each stock’s gains from February 21 to February 26, according to Markets Insider.
Novavax - Stanley Erck Shares held: 46,776
Gain: $70,164
-
Rajiv Modi - Shares held: 125,000.
Gain: $187,500
Gilead - John Milligan Shares held: 1,574,306
Gain: $7,871,530
-
John Martin Shares held: 2,887,225
Gain: $14,436,125
Moderna - Timothy Springer Shares held: 4,272,968 Gain: $46,703,540
-
Stephane Bancel Shares held: 7,456,986
Gain: $81,504,857
-
Robert Langer Shares held: 11,509,537
Gain: $125,799,239
https://greatgameindia.com/this-small-elite-group-made-millions-from-coronavirus/